# Shape Memory Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shape-memory-medical

- Industry: Medical Devices & Equipment
- Headquarters: San Jose, US
- Website: www.shapemem.com
- Total disclosed funding: $42M
- Latest round: Series C (Feb 6, 2024)
- Investors on record: 5

## About

Founded in 2009 and based in California, US, Shape Memory Medical Inc. is a medical device company. In February 2024, Shape Memory Medical, Inc. raised USD 30.49 million in Series C funding led by Earlybird Venture Capital, HBM Partners, MedFocus Funds, Wexford Capital, and Emergent Medical Ventures. The Series C funding values Shape Memory Medical, Inc. at USD 83.86 million post-money. As of 2024, the company is led by its CEO and president, Ted Ruppel.

Shape Memory Medical develops and offers the IMPEDE Embolization Plug, a peripheral vascular and neurovascular embolization device based on shape memory polymer foams used for the treatment of peripheral vascular diseases. The firm’s peripheral embolization products include the IMPEDE® and IMPEDE-FX Embolization Plugs and the IMPEDE-FX RapidFill® Device.

The company plans to use the funds raised in February 2024 to accelerate the clinical and market development of its technology, expand its sales and marketing tactics, and conduct research and development for its product pipeline.

## Funding rounds

- Series C, Feb 6, 2024, $30M — HBM Partners, Wexford Capital, Earlybird, Emergent Medical Ventures, MedFocus Funds
- Series B, May 4, 2020, $1.4M — HBM Partners
- Series B, Feb 4, 2019, $3M — HBM Partners
- Series B, Jul 19, 2017, $7M — HBM Partners, Wexford Capital, Emergent Medical Ventures, MedFocus Funds

## Investors

- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B, Series C
- Wexford Capital — Series B, Series C
- Emergent Medical Ventures (https://capitalatlas.ai/funds/emergent-medical-ventures) — Series B, Series C
- MedFocus Funds (https://capitalatlas.ai/funds/medfocus-funds) — Series B, Series C
- Earlybird (https://capitalatlas.ai/funds/earlybird) — Series C